Delving into the Latest Updates on Becocalcidiol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Becocalcidiol (USAN/INN), 2-MBISP, 2-MBP

+ [3]

Target

VDR

Action

agonists

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Plaque psoriasis

Originator Organization

QuatRx Pharmaceuticals Co.

Active Organization-

Inactive Organization

QuatRx Pharmaceuticals Co.

Deltanoid Pharmaceuticals, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H36O2

InChIKeyQSLUXQQUPXBIHH-YHSKWIAJSA-N

CAS Registry524067-21-8

Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia. Calcipotriol, the most thoroughly studied of the vitamin D analogs, was first approved in Europe in the early 1990s. It has been shown to be comparable or slightly more effective than class II corticosteroid ointments. However, patients had reduced levels of parathyroid hormone; mean serum and urine calcium were increased during treatment and hypercalciuria was observed. These effects were reversible with discontinuation of therapy. Thus, while calcipotriol ointment was shown to be effective, the potential for alterations in calcium homeostasis have limited its use to 100 g of ointment per week (0.5 mg calcipotriol/week). Work has continued on the creation of new vitamin D analogs, such as COL-121, with the intent of eliminating the adverse effects of hypercalcemia and hypercalciuria with a compound that is more stable and more easily administered.

Start Date01 Jan 2008

Sponsor / Collaborator

Deltanoid Pharmaceuticals, Inc.

NCT00373516

/ CompletedPhase 2

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Study of the Safety and Efficacy of Two Dosing Regimens of QRX-101 (Becocalcidiol) Ointment in the Treatment of Plaque-Type Psoriasis

The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks

Start Date01 Sep 2004

Sponsor / Collaborator

QuatRx Pharmaceuticals Co.

100 Clinical Results associated with Becocalcidiol

Login to view more data

100 Translational Medicine associated with Becocalcidiol

Login to view more data

100 Patents (Medical) associated with Becocalcidiol

Login to view more data

19

Literatures (Medical) associated with Becocalcidiol

01 Apr 2026·Biotechnology Journal

Multi‐omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy‐Induced Nausea and Vomiting in Small Cell Lung Cancer

Article

Author: Chen, Jun ; Xin, Yu ; Cui, Jia ; Han, Xu ; Sun, Qiang‐Guo ; Zang, Dan

ABSTRACT:

Small cell lung cancer (SCLC) is a highly aggressive malignancy, and chemotherapy frequently causes nausea and vomiting, which can impair treatment tolerance. Because thalidomide (THD) has shown potential clinical benefit in alleviating nausea and anorexia, we investigated whether its effects might be associated with changes in gut microbial composition and metabolite profiles. Fecal samples were collected from patients with SCLC and categorized into THD‐treated and control groups. Metagenomic sequencing and nontargeted metabolomic profiling were performed to characterize microbial composition and metabolic signatures. THD treatment was also associated with higher microbial alpha diversity and increased abundance of genera such as Eubacterium and Prevotella . Metabolomic analysis identified several differential metabolites, including hydrogenated MDI, becocalcidiol, β‐octylglucoside, and azelaic acid. Collectively, these findings suggest that the gut microbiota‐metabolite axis may be associated with the potential effects of THD on CINV and anorexia in patients with SCLC. The identified microbial taxa and metabolites may serve as candidate biomarkers or potential therapeutic targets, although further validation in larger studies is necessary.

01 Jun 2015·Biochemical and biophysical research communicationsQ3 · BIOLOGY

Vitamin D deficiency independent of hypocalcemia elevates blood pressure in rats

Q3 · BIOLOGY

Article

Author: Sundersingh, Flora ; DeLuca, Hector F ; Plum, Lori A

Essential hypertension is a polygenic disorder with a complex and multifactorial nature. Although no single gene is responsible, multiple genes provide incremental contributions to this disorder. Vitamin D is a primary regulator of calcium homeostasis. Epidemiological and clinical studies appear to point to a role for vitamin D in hypertension but direct experimental evidence is lacking. Sprague-Dawley rats were made vitamin D deficient by feeding a purified vitamin D-deficient diet and eliminating all sources of ultraviolet light. Vitamin D deficiency was confirmed by very low serum calcium levels. Blood pressure was measured in conscious rats non-invasively with a volume pressure recording system. Vitamin D deficiency results in elevated blood pressures independent of serum calcium concentration. The administration of 1α,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and a less calcemic analog, 2-methylene-19-nor-20(S)-1α-hydroxyl-bishomopregnacalciferol (2MbisP) significantly reduced blood pressure in these rats. Thus, vitamin D status is one of the determining factors regulating blood pressure.

01 Nov 2011·Archives of biochemistry and biophysicsQ3 · BIOLOGY

Supplementation by vitamin D compounds does not affect colonic tumor development in vitamin D sufficient murine models

Q3 · BIOLOGY

Article

Author: Kathleen J. Krentz ; Amy A. Irving ; Lori A. Plum ; Norman Drinkwater ; Hector F. DeLuca ; Dawn M. Albrecht ; Linda Clipson ; William F. Dove ; James M. Amos-Landgraf ; Richard B. Halberg

Epidemiological studies indicate that sunlight exposure and vitamin D are each associated with a lower risk of colon cancer. The few controlled supplementation trials testing vitamin D in humans reported to date show conflicting results. We have used two genetic models of familial colon cancer, the Apc(Pirc/+) (Pirc) rat and the Apc(Min/+) (Min) mouse, to investigate the effect of 25-hydroxyvitamin D(3) [25(OH)D(3)] and two analogs of vitamin D hormone on colonic tumors. Longitudinal endoscopic monitoring allowed us to test the efficacy of these compounds in preventing newly arising colonic tumors and in affecting established colonic tumors. 25(OH)D(3) and two analogs of vitamin D hormone each failed to reduce tumor multiplicities or alter the growth patterns of colonic tumors in the Pirc rat or the Min mouse.

100 Deals associated with Becocalcidiol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08868	-	-	DB04891

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	Phase 2	United States	QuatRx Pharmaceuticals Co.	01 Sep 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00373516 (Pubmed \| Br J Dermatol)	Phase 2	Psoriasis vulgaris	-	Placebo	krdkmsooiv(hraxhevebh): P-Value = 0.002	Positive	01 Aug 2007
				Becocalcidiol 75 microg g(-1) twice daily